INNOVATE Corp
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(18) Basic and Diluted Loss Per Common Share
- Basic and Diluted Loss Per Common Share
Earnings (loss) per share ("EPS") is calculated using the two-class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards and Series C Preferred Stock that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, shares of any unvested restricted stock and Series C Preferred Stock of the Company are considered participating securities; however, unvested restricted stock do not participate in losses and, as such, are excluded from the computation of basic earnings (loss) per share during periods of net losses. The dilutive effect, if applicable, of stock options and their equivalents (including non-vested stock issued under stock-based compensation plans), is computed using the "if-converted method" if this measurement is determined to be more dilutive than the treasury stock method in a period.
The Company hadno dilutive common stock equivalents during the three and nine months ended September 30, 2024, and 2023, due to the results from continuing operations being a loss, net of tax. For the three and nine months ended September 30, 2024,151,806 and 111,449, respectively, of common stock equivalents from unvested restricted stock were excluded from the weighted average number of shares used to calculate diluted loss per share as their inclusion would have been anti-dilutive. Other instruments that may, in the future, if the average market price of the Company's stock exceeds the conversion prices, have a dilutive effect on earnings per share, but were excluded from the computations of diluted net loss per share, and may be excluded from computations of diluted earnings (loss) per share in the future, are: convertible preferred stock, convertible debt, stock options and restricted stock units. Refer to Note 14. Share-based Compensation and Note 15. Equity and Temporary Equity for additional information on INNOVATE's equity instruments.
The following table presents a reconciliation of net loss to net loss used in the basic and diluted EPS calculations (in millions, except shares and per share amounts):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss | $(16.2) | $(8.6) | $(22.4) | $(28.3) |
| Net loss attributable to non-controlling interest and redeemable non-controlling interest | 1.2 | 1.6 | 4.4 | 2.4 |
| Net loss attributable to INNOVATE Corp. | (15.0) | (7.0) | (18.0) | (25.9) |
| Less: Preferred dividends | 0.3 | 0.3 | 0.9 | 2.1 |
| Net loss attributable to common stockholders and participating preferred stockholders | $(15.3) | $(7.3) | $(18.9) | $(28.0) |
| Loss allocable to common shares: | ||||
| Participating shares | ||||
| Weighted average common shares outstanding | 12,966,322 | 7,841,847 | 9,928,679 | 7,801,240 |
| Unvested restricted stock | — | — | — | — |
| Series C Preferred stock | — | — | 1,265,381 | — |
| Total | 12,966,322 | 7,841,847 | 11,194,060 | 7,801,240 |
| Percentage of loss allocated to: | ||||
| Common stock | 100.0% | 100.0% | 88.7% | 100.0% |
| Unvested restricted stock | —% | —% | —% | —% |
| Series C Preferred stock | —% | —% | 11.3% | —% |
| Numerator for loss per share | ||||
| Net loss attributable to common stock holders, basic and diluted | $(15.3) | $(7.3) | $(16.8) | $(28.0) |
| Net loss attributable to Series C holder, basic and diluted | $— | $— | $(2.1) | $— |
| Denominator for loss per share: | ||||
| Weighted average common shares outstanding - basic and diluted | 12,966,322 | 7,841,847 | 9,928,679 | 7,801,240 |
| Weighted average Series C shares outstanding - basic and diluted | — | — | 1,265,381 | — |
| Loss per common share - basic and diluted | $(1.18) | $(0.93) | $(1.69) | $(3.59) |
| Loss per Series C share - basic and diluted | $— | $— | $(1.69) | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.